American Century Companies’s Ultragenyx Pharmaceutical RARE Stock Holding History

American Century Companies’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,780	Closed	-$456K	–	2981
2026 Q1	$456K	Buy	+21,780	New	+$490K	﹤0.01%	2536
2025 Q4	–	Sell	-10,054	Closed	-$302K	–	2872
2025 Q3	$302K	Hold	10,054	–	–	﹤0.01%	2625
2025 Q2	$366K	Buy	+10,054	New	+$362K	﹤0.01%	2611
2022 Q2	–	Sell	-3,048	Closed	-$221K	–	2375
2022 Q1	$221K	Buy	3,048 +90	+3%	+$6.26K	﹤0.01%	2161
2021 Q4	$249K	Buy	2,958 +229	+8%	+$18.6K	﹤0.01%	2143
2021 Q3	$246K	Sell	2,729 -6,005	-69%	-$543K	﹤0.01%	2141
2021 Q2	$833K	Sell	8,734 -135,156	-94%	-$14.1M	﹤0.01%	1640
2021 Q1	$16.4M	Sell	143,890 -6,715	-4%	-$914K	0.01%	681
2020 Q4	$20.8M	Sell	150,605 -3,176	-2%	-$377K	0.02%	600
2020 Q3	$12.6M	Sell	153,781 -17,906	-10%	-$1.48M	0.01%	659
2020 Q2	$13.4M	Buy	171,687 +61,158	+55%	+$4.05M	0.01%	604
2020 Q1	$4.91M	Buy	110,529 +2,618	+2%	+$136K	0.01%	729
2019 Q4	$4.61M	Buy	107,911 +42,069	+64%	+$1.74M	﹤0.01%	814
2019 Q3	$2.82M	Buy	65,842 +2,947	+5%	+$160K	﹤0.01%	916
2019 Q2	$3.99M	Buy	62,895 +8,980	+17%	+$572K	﹤0.01%	881
2019 Q1	$3.74M	Sell	53,915 -4,238	-7%	-$242K	﹤0.01%	876
2018 Q4	$2.53M	Buy	58,153 +2,588	+5%	+$141K	﹤0.01%	933
2018 Q3	$4.24M	Sell	55,565 -410	-0.7%	-$33.3K	﹤0.01%	893
2018 Q2	$4.3M	Buy	55,975 +19,255	+52%	+$1.24M	﹤0.01%	882
2018 Q1	$1.87M	Buy	36,720 +997	+3%	+$50.2K	﹤0.01%	1010
2017 Q4	$1.66M	Buy	35,723 +5,752	+19%	+$282K	﹤0.01%	1037
2017 Q3	$1.6M	Sell	29,971 -633	-2%	-$37.5K	﹤0.01%	1072
2017 Q2	$1.9M	Sell	30,604 -3,839	-11%	-$231K	﹤0.01%	1045
2017 Q1	$2.33M	Sell	34,443 -146	-0.4%	-$11.1K	﹤0.01%	1018
2016 Q4	$2.43M	Sell	34,589 -7,670	-18%	-$544K	﹤0.01%	1005
2016 Q3	$3M	Buy	42,259 +693	+2%	+$44.2K	﹤0.01%	996
2016 Q2	$2.03M	Buy	41,566 +3,874	+10%	+$251K	﹤0.01%	1024
2016 Q1	$2.39M	Sell	37,692 -1,464	-4%	-$95.8K	﹤0.01%	966
2015 Q4	$4.39M	Buy	39,156 +4,943	+14%	+$494K	0.01%	863
2015 Q3	$3.29M	Buy	34,213 +13,970	+69%	+$1.6M	﹤0.01%	938
2015 Q2	$2.07M	Buy	+20,243	New	+$1.57M	﹤0.01%	1020

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

American Century Companies's RARE Position: Q2 2026 in Review

American Century Companies sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 21,780 shares — an estimated $456K sold.

American Century Companies first reported a position in RARE in Q2 2015 and held it in 31 quarters. The position peaked at $20.8M in Q4 2020. 203 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

American Century Companies reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
American Century Companies sold 21,780 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $456K.
American Century Companies first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and held it in 31 quarters.
American Century Companies's Ultragenyx Pharmaceutical position peaked at $20.8M in Q4 2020.
203 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.